Using ASO‐mediated gene downregulation, a compound to suppress LRRK2 expression has shown efficacy in a PD mouse model1, 22 and is currently undergoing evaluation in a phase I clinical trial (ClinicalTrials.gov: NCT03976349), with data suggesting that an allele‐specific approach may be needed. Here, LRRK2 is linked to Parkinson disease.